Shek, Naomi http://orcid.org/0009-0003-6532-855X
Choy, Anna-Maria http://orcid.org/0000-0002-4052-0591
Lang, Chim C.
Miller, Bruce E. http://orcid.org/0000-0003-3904-3182
Tal-Singer, Ruth
Bolton, Charlotte E.
Thomson, Neil C.
Chalmers, James D.
Bown, Matt J.
Newby, David E.
Khan, Faisel
Huang, Jeffrey T. J. http://orcid.org/0000-0002-6879-3014
Funding for this research was provided by:
Heart Research UK (NET21-100006, NET21-2302)
Chief Scientist Office (CGA-17-07)
Pfizer (GU-022)
RCUK | Medical Research Council
Article History
Received: 23 September 2023
Accepted: 14 February 2024
First Online: 27 February 2024
Competing interests
: J.T.J.H. received funding from Wyeth/Pfizer, GSK, Chief Scientific Office (Scotland), Tenovus Scotland for the studies reported in the manuscript. R.T.S. received personal fees from Roche, AstraZeneca, Vocalis Health, Teva, Immunomet, Renovion, Samay Health, Itay and Beyond, and ENA Respiratory. Retiree and shareholder of GSK and holds share options in ENA Respiratory. CEB received grants for investigator-sponsored studies, with funding to the institution from AstraZeneca, GSK, Chiesi, Boehringer, and Novartis. CEB’s institution received funding from AstraZeneca for further AZ-sponsored study. C.E.B. is on iDMC with Roche. C.E.B.’s institution has received grant funding for other COPD research from NIHR, the British Lung Foundation, and Horizon2020. The remaining authors do not have competing interests.